Folic Acid

Folic Acid

SCHEMBL6470174

Nc1nc(O)c2nc(CNc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)cnc2n1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.73
MEN1 O00255 2/20 0.73
ALDH1A1 P00352 2/20 0.73
TYMS P04818 2/20 0.73
POLB P06746 2/20 0.73
HPGD P15428 2/20 0.73
KMT2A Q03164 2/20 0.73
HSD17B10 Q99714 2/20 0.73
TDP1 Q9NUW8 2/20 0.73
GAA P10253 1/20 0.73
AKR1B1 P15121 1/20 0.73
TSHR P16473 1/20 0.73
PTGS2 P35354 1/20 0.73
DHFR P00374 9/20 0.67
TLR4 O00206 1/20 0.61
LMNA P02545 1/20 0.61
TP53 P04637 1/20 0.61
GLA P06280 1/20 0.61
HMGB1 P09429 1/20 0.61
MAPT P10636 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Folic Acid SCHEMBL3878 1.00 KDM4E (0.73) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL29677832 1.00 KDM4E (0.73) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL12148554 1.00 KDM4E (0.73) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL1887022 0.99 KDM4E (0.72) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL12497751 0.99 KDM4E (0.72) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL23388805 0.99 KDM4E (0.72) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL19837676 0.99 KDM4E (0.72) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL652283 0.99 KDM4E (0.72) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL22441084 0.99 KDM4E (0.72) KDM4EMEN1ALDH1A1TYMSPOLB
Folic Acid SCHEMBL842691 0.99 KDM4E (0.72) KDM4EMEN1ALDH1A1TYMSPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103719632-A Livestock feed containing nutlet components and livestock feeding method WANG ZHONG 2014-04-16 CN claimed
CN-103704534-A Dairy cow feed containing nutlet components and method for breeding dairy cows by stages WANG ZHONG 2014-04-09 CN claimed
CN-103689235-A Laying hen feed taking nuts as feed components and classified feeding method of laying hen WANG ZHONG 2014-04-02 CN claimed
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 US claimed
EP-1303311-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF Neurochem, Inc. (CA) 2003-04-23 EP claimed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 US claimed
WO-2002007781-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF NEUROCHEM INC. (CA) 2002-01-31 WO claimed
CN-119585616-A Biomarkers and methods for treating NSCLC 天境生物科技(上海)有限公司 2025-03-07 CN disclosed
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-02-13 US disclosed
CN-113607945-B Combination therapy of anti-HER 2 antibody-drug conjugates and Bcl-2 inhibitors 豪夫迈·罗氏有限公司 2025-01-28 CN disclosed
CN-118715239-A Dual cytokine fusion proteins comprising multi-subunit cytokines 德卡生物科学公司 2024-09-27 CN disclosed
CN-118695868-A Dual cytokine fusion proteins comprising IL-10 and adoptive cell therapies or dual-specific T cell adaptors for treating cancer 德卡生物科学公司 2024-09-24 CN disclosed
CN-118147029-A Engineered immunostimulatory bacterial strains and uses thereof 阿克蒂姆治疗有限公司 2024-06-07 CN disclosed
WO-2007092847-A2 SOLID PHASE SYNTHESIS OF ACRIDINIUM DERIVATIVES SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2007-08-16 WO disclosed
US-20070191352-A1 Inhibition of tau-tau-association THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2007-08-16 US disclosed
US-20070041934-A1 Dendrimer based compositions and methods of using the same REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-02-22 US disclosed
US-6908941-B2 Topical applying; animal growth regulators THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT 2005-06-21 US disclosed
US-20040265345-A1 Treatment of skin damage using acetyl carnitine and lipoic acid N.V. PERRICONE LLC 2004-12-30 US disclosed
US-20040081634-A1 HAIR AND NAIL TREATMENTS USING ALKANOLAMINES THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT 2004-04-29 US disclosed
US-4087556-A STABILIZATION WITH PHOSPHATES, CITRATES, ASCORBATES, ENCAPSULATION CHEMISCHE INDUSTRIE RANDSTAD, N.V. (NE) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT KDM4E 2549/4885MEN1 163/4885ALDH1A1 1109/4885
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 KDM4E 3994/4885MEN1 605/4885ALDH1A1 3305/4885
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 KDM4E 3994/4885MEN1 605/4885ALDH1A1 3305/4885
US-20040265345-A1 Treatment of skin damage using acetyl carnitine and lipoic acid CUTA, LRAT, ACACA KDM4E 3641/4885MEN1 4866/4885ALDH1A1 145/4885
US-20070191352-A1 Inhibition of tau-tau-association MAPT, PSEN1, PSEN2 KDM4E 3570/4885MEN1 4053/4885ALDH1A1 4307/4885
US-20040081634-A1 HAIR AND NAIL TREATMENTS USING ALKANOLAMINES TYR, DNER, KRT18 KDM4E 129/4885MEN1 2409/4885ALDH1A1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.